About us

The Cellular and Molecular Therapies (CMT) function within NHS Blood and Transplant (NHSBT) is responsible for the routine provision of stem cells for transplantation across the country and for the development and manufacture of novel advanced cell therapies that fall under Medicines and Healthcare products Regulatory Agency (MHRA) regulations as advanced therapy medicinal products (ATMPs).

CMT operates from six UK sites, consisting of six Human Tissue Authority (HTA) licensed, Joint Accreditation Committee ISCT-Europe & EBMT (JACIE) accredited cell processing facilities serving regional bone and marrow transplant programmes, three MHRA licensed facilities supporting ATMP manufacture including the Clinical Biotechnology Centre (CBC) preparing GMP-grade DNA plasmids and viral vectors.